Citations

Clear

4564 citation(s) found for "Yu, Virginia".

A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes
Kudva, Yogish C. , Raghinaru, Dan, Lum, John W. , Graham, Timothy E., Liljenquist, David R., Spanakis, Elias K. , Pasquel, Francisco J. , Ahmann, Andrew , Blevins, Thomas , Kruger, Davida , Brown, Sue A. , Weinstock, Ruth S. , Spaic, Tamara , Hirsch, Irl B., Broyles, Frances E. , Raskin, Philip, Desjardins, Donna, Terry, Adrienne, Singh, Lakshmi G., Davis, Georgia M. , Schmid, Caleb, Kravarusic, Jelena, Coyne, Kasey, Casaubon, Luis, Espinosa, Valerie, Jones, Jaye K., Estrada, Kathleen, Afreen, Samina , Levister, Camilla, O’Malley, Grenye , Liu, Selina , Marks, Sheryl, Peleckis, Amy J. , Tardio, Vanessa , Kurek, Corey, Luker, Ryan, Churchill, Jade, Dean, Ariel, Dennis, Brittany , Fronczyk, Evelyn, Perez, Jennifer, Mukhashen, Shereen, Dhillon, Jasmeen, Ipek, Aslihan, Bzdick, Suzan, Atakov-Castillo, Astrid , Driscoll, Marsha, Averkiou, Xenia, Dalton-Bakes, Cornelia, Moore, Adelyn, Jordan, Lin F., Lesniak, Amanda, Pinsker, Jordan E. , Sasson-Katchalski, Ravid, Campos, Tiffany, Spanbauer, Charles , Kollman, Craig, Beck, Roy W., Rickels, Michael R , Pasqua, Melissa-Rosina , Pinsker, Jordan E , Pasquel, Francisco J , Ahn, David , Aleppo, Grazia , Levy, Carol J. , Steenkamp, Devin W , Rickels, Michael R. , Tsoukas, Michael A. , Hatipoğlu, Betül , Jones, Jaye K., Marks, Sheryl, Tajrishi, Farbod Zahedi , Dean, Ariel, Moore, Adelyn, Lesniak, Amanda, Kanapka, Lauren , Kollman, Craig , Beck, Roy W.

Mayo Clinic

New England Journal of Medicine | March 19, 2025 | Volume: 392 | Issue: 18 | Pages: 1801-1812

10.1056/nejmoa2415948 | PMID 40105270 Get It

TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation and Fibrosis Improve with Treatment
Osterhout, Robin , Channick, Richard, Frantz, R, McLaughlin, V.V., Vachiéry, J, Roscigno, Robert F., Mottola, David, Sitapara, Ravi, Aranda, R., Zisman, Lawrence S. , Bruey, Jean‐Marie, Zamanian, R.T., Ghofrani, Hossein Ardeschir , Osterhout, Robin E. , Benza, Raymond L. , Chin, Kelly M , Frantz, Robert P. , Hemnes, Anna R. , Howard, Luke , Sitbon, Olivier , Sitapara, Ravikumar

Mayo Clinic

Pneumologie | March 18, 2025 | Volume: 79 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1804783 Get It

Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704
Sorror, Mohamed L. , Saber, Wael , Logan, Brent R. , Geller, Nancy L. , Bellach, Anna , Kou, Jianqun, McCarty, John M. , Knight, Thomas G. , Runaas, Lyndsey, Johnston, Laura, Nakamura, Ryotaro , Jarrett, Lori, Mishra, Asmita , Uberti, Joseph P., Morris, Lawrence E. , Nadiminti, Kalyan , Olin, Rebecca L. , Sobecks, Ronald , Wall, Sarah , Mattila, Deborah, Protz, Bailey, Horowitz, Mary M. , Geller, Nancy , Knight, Thomas G , Nakamura, Ryotaro , Dahi, Parastoo B , Saultz, Jennifer N , Imus, Philip H , Hogan, William J , Bhatt, Vijaya Raj , Artz, Andrew S , Sorror, Mohamed , Wood, William A. , Walston, Jeremy D , Jarrett, Lori, McCurdy, Shannon , Hogan, William J. , Bhatt, Vijaya Raj , Maakaron, Joseph E. , Devine, Steven M. , Artz, Andrew

Mayo Clinic

Blood Advances | March 18, 2025 | Volume: 9 | Issue: 13 | Pages: 3268-3280

10.1182/bloodadvances.2025015793 | PMID 40101246 Get It

Abstract Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for older adults with hematologic malignancies. Concerns on nonrelapse mortality (NRM) in older adults limit allo-HCT utilization. We executed a prospective, observational study BMT-CTN 1704 (Blood and Marrow Transplant Clinical Trials Network) enrolling allo-HCT recipients aged ≥60 years from 49 centers in the United States. We analyzed associations between 13 measurements of older adult health and NRM within 1 year to construct a comprehensive health assessment risk model (primary-CHARM) using multivariate Fine-Gray model and grouped penalized variable selection. Two machine learning (ML) models (Cox and pseudo-value boosting) were also explored. Models’ performances were compared using area under the curve (AUC), with bootstrap and cross-validation sampling to correct for optimism, decision curve analysis (DCA), calibration, and Brier scores. Among 1105 patients with median age of 67 (range, 60-82) years who received allo-HCT, NRM was 14.4% and overall survival (OS) 71.7% at 1 year. Factors statistically selected for inclusion in primary-CHARM were higher comorbidity burden, lower albumin, higher C-reactive protein, older age, higher weight-loss percentage, lower patient-reported performance score, and cognitive impairment. Primary-CHARM scores were independently associated with higher NRM (hazard ratio [HR], 2.72; P < .0001) and worse OS (HR, 2.09; P < .0001). Bootstrap bias–corrected AUC for primary-CHARM was 0.591. Comparing primary-CHARM with HCT-comorbidity index and 2 ML-CHARM models, calibration, Brier score, and DCA analysis favored primary-CHARM. Primary-CHARM, with mostly simple and readily available parameters, risk stratifies older adults for allo-HCT. Adopting primary-CHARM in practice may promote broader use of HCT by quantifying risk and enhance the design of strategies to improve outcomes. This trial was registered at www.ClinicalTrials.gov as #NCT03992352.
Sociodemographic Characteristics of Patients Seen at Vascular Anomaly Centers in the United States
Sisk, Bryan A. , Eng, Whitney , Mack, Joana M. , Tran, Andrew , Ogino, Jayme , Pearson, Erika , Bies, Joshua J., Smink, Gayle , Shah, Sonal D. , Mohney, Lindsey , Fassel, Hannah, Schulte, Rachael , Tessem, Renae A., Swaminathan, Neeraja , McLean, Thomas W. , Alturky, Sara , Wu, Melinda , Atkinson, Autumn, Al‐Huniti, Ahmad , Massey, Gita , Engel, Elissa , Echols, Tyson C. , Kumar, Sumukh Arun , Fox, Michael D. , King, Katherine A., Mack, Joana , Pearson, Erika , Shah, Sonal D , Swaminathan, Neeraja , McLean, Thomas W , Blatt, Julie , Massey, Gita , Ricci, Kiersten , Echols, Tyson , Fox, Michael , Sisk, Bryan A , Aye, Jamie M. , Chang, Vivian Y. , Hogeling, Marcia , Atkinson, Autumn

Mayo Clinic

Pediatric Blood & Cancer | March 17, 2025 | Volume: 72 | Issue: 6 | Pages: No page available

10.1002/pbc.31661 | PMID 40091541 Get It

ABSTRACTPatients with vascular anomalies (VAs) require expert multidisciplinary care. No prior studies have characterized the sociodemographic characteristics across multiple VA centers. We collected data on 5783 patients receiving care at 20 VA centers between July 1, 2020 through December 31, 2022. Male patients were underrepresented compared to the state‐level census data at 17/20 centers. Black and Asian patients were underrepresented at 14/20 and 12/20 centers, respectively. The median distance to the hospital was 48 miles, and median age was 12.0 years. These data suggest that race, sex, age, and distance from the hospital could impede the ability to access expert VA care.
Belumosudil in diffuse cutaneous systemic sclerosis: a randomized, double-blind, open-label extension, placebo-controlled, phase 2 study
Chung, Leland W.K. , Steen, Virginia , Furst, Daniel E. , Castelino, Flavia V. , Trojanowski, Marcin A. , Domsic, Robyn T. , Katsumoto, Tamiko R. , Goulaouic, Hélène , Wang, Hong , Espinasse, Melanie, El‐Chemaly, Souheil , Wang, Rui , Chung, Lorinda , Furst, Daniel E , Domsic, Robyn T , Katsumoto, Tamiko R , Wang, Rui , Silver, Richard M. , Spiera, Robert , Rodríguez-Pla, Alicia

Mayo Clinic

Rheumatology | March 15, 2025 | Volume: 64 | Issue: 7 | Pages: 4299-4308

10.1093/rheumatology/keaf062 | PMID 40088930 Get It

Abstract Objectives To determine the efficacy, safety and pharmacodynamics of belumosudil in patients with diffuse cutaneous systemic sclerosis (dcSSc) treated with background immunosuppressive therapies. Methods Eligible patients were randomised 1:1:1 to receive belumosudil 200 mg once daily (QD) or twice daily (BID), or placebo for 28 weeks (double-blind period). After unblinding, the patients who received belumosudil continued the same dose, whereas the patients who received placebo were re-randomised for one of the belumosudil doses for 24 weeks (open-label extension). Results Thirty-five and 31 patients were treated in the double-blind and open-label periods, respectively. The study was terminated prematurely, and target enrolment was not met. The primary end point, of CRISS score ≥0.60 at week 24, did not exhibit an efficacy signal in the belumosudil vs placebo groups [odds ratio: 1.06 (0.19–5.82; P = 0.9472) for the QD, and 0.39 (0.07–2.35; P = 0.3078) for the BID group]. Belumosudil was well tolerated and exhibited similar safety profiles in both double-blind and open-label periods. Tissue-based RNA sequencing analysis revealed FOXP3 upregulation and STAT3, IL23A and TGF-β downregulation in patients with CRISS score ≥0.60, which supported the mechanism of action of belumosudil. In blood and tissue samples, trends of decreased fibrosis biomarker levels were seen in the belumosudil-treated group vs placebo. Conclusion Efficacy signal for belumosudil could not be detected. Signalling pathway modulation analysis supported the mechanism of action of belumosudil. A trend for decreased fibrosis-related biomarkers was observed in the belumosudil-treated group. Trial registration ClinicalTrials.gov, https://clinicaltrials.gov, NCT03919799.
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma
Banerjee, Rahul , Richards, Alicia, Midha, Shonali , Afrough, Aimaz , Anwer, Faiz , Atanackovic, Djordje , Bachanová, Veronika , Bhurtel, Jenny , Cicero, Kara I. , Davis, James A. , Dhakal, Binod , Ferreri, Christopher J. , Forsberg, Peter A. , Freeman, Ciara L. , Khouri, Jack , Kumar, Anupama, Liu, Yuxin , Mikkilineni, Lekha , Peres, Lauren C. , Purvey, Sneha , Raza, Shahzad , Sborov, Douglas W. , Shune, Leyla , Wagner, Charlotte B , Zanwar, Saurabh , Sidana, Surbhi , Patel, Krina K. , Kumar, Shaji , Lin, Yi , Martin, Thomas G. , Voorhees, Peter M. , Anderson, Larry D. , Cowan, Andrew J., Chhabra, Saurabh , Davis, James A , Dhakal, Binod , Freeman, Ciara L , Herr, Megan M. , Jain, Tania , Khouri, Jack , Kocoglu, Mehmet H , McGuirk, Joseph , Parrondo, Ricardo D , Pasvolsky, Oren , Sborov, Douglas W , Wagner, Charlotte , Zanwar, Saurabh S , Sidana, Surbhi , Patel, Krina , Kumar, Shaji K , Voorhees, Peter , Anderson, Larry D , Kaur, Gurbakhash , Bachanova, Veronika , Banerjee, Rahul , Raza, Shahzad , Anwer, Faiz , Atrash, Shebli , Beitinjaneh, Amer , Puglianini, Omar Castañeda , Chhabra, Saurabh , Dima, Danai , Jain, Tania , Janakiram, Murali , Kocoglu, Mehmet H. , Locke, Frederick L. , McGuirk, Joseph P. , Nadeem, Omar , Pasvolsky, Oren , Reshef, Ran , Richard, Shambavi , Rossi, Adriana , Hansen, Doris K. , Kaur, Gurbakhash

Mayo Clinic

Blood Advances | March 15, 2025 | Volume: 9 | Issue: 9 | Pages: 2336-2340

10.1182/bloodadvances.2025016131 | PMID 40088469 Get It

Machine learning–based model to predict long-term tumor control and additional interventions following pituitary surgery for Cushing’s disease
Shinya, Yuki , Hong, Sukwoo , Erickson, Dana , Davidge‐Pitts, Caroline , Nguyen, Ryan , Nieves, Antonio Bon, Sáez-Alegre, Miguel , Celda, María Peris, Pollock, Bruce E. , Meyer, Fredric B. , Atkinson, John L. D., Herndon, Justine S, Bon Nieves, Antonio, Sáez Alegre, Miguel, Pinheiro Neto, Carlos D, Peris Celda, Maria, Shinya, Yuki , Ghaith, Abdul Karim , Bancos, Irina , Herndon, Justine , Morshed, Ramin A. , Pinheiro‐Neto, Carlos , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurosurgery | March 14, 2025 | Volume: 143 | Issue: 1 | Pages: 184-193

10.3171/2024.10.jns241338 | PMID 40085940 Get It

OBJECTIVE In this study, the authors aimed to establish a supervised machine learning (ML) model based on multiple tree-based algorithms to predict long-term biochemical outcomes and intervention-free survival (IFS) after endonasal transsphenoidal surgery (ETS) in patients with Cushing’s disease (CD). METHODS The medical records of patients who underwent ETS for CD between 2013 and 2023 were reviewed. Data were collected on the patient’s baseline characteristics, intervention details, histopathology, surgical outcomes, and postoperative endocrine functions. The study’s primary outcome was IFS, and the therapeutic outcomes were labeled as "under control" or "treatment failure," depending on whether additional therapeutic interventions after primary ETS were required. The decision tree and random forest classifiers were trained and tested to predict long-term IFS based on unseen data, using an 80/20 cohort split. RESULTS Data from 150 patients, with a median follow-up period of 56 months, were extracted. In the cohort, 42 (28%) patients required additional intervention for persistent or recurrent CD. Consequently, the IFS rates following ETS alone were 83% at 3 years and 78% at 5 years. Multivariable Cox proportional hazards analysis demonstrated that a smaller tumor diameter that could be detected by MRI (hazard ratio 0.95, 95% CI 0.90–0.99; p = 0.047) was significantly associated with greater IFS. However, the lack of tumor detection on MRI was a poor predictor. The ML-based model using a decision tree model displayed 91% accuracy (95% CI 0.70–0.94, sensitivity 87.0%, specificity 89.0%) in predicting IFS in the unseen test dataset. Random forest analysis revealed that tumor size (mean minimal depth 1.67), Knosp grade (1.75), patient age (1.80), and BMI (1.99) were the four most significant predictors of long-term IFS. CONCLUSIONS The ML algorithm could predict long-term postoperative endocrinological remission in CD with high accuracy, indicating that prognosis may vary not only with previously reported factors such as tumor size, Knosp grade, gross-total resection, and patient age but also with BMI. The decision tree flowchart could potentially stratify patients with CD before ETS, allowing for the selection of personalized treatment options and thereby assisting in determining treatment plans for these patients. This ML model may lead to a deeper understanding of the complex mechanisms of CD by uncovering patterns embedded within the data.
Microsurgical Resection Versus Stereotactic Radiosurgery for Trigeminal Schwannoma: A Meta-Analysis of 949 Patient Treatment Outcomes
Hallak, Hana , Pais, Alex, Metzler, Ashley, Sheehan, Jason , Kshettry, Varun R. , Link, Michael J., Celda, María Peris, Morshed, Ramin A. , Pais, Alex, Gompel, Jamie J. Van , Link, Michael J.

Mayo Clinic

Neurosurgery | March 13, 2025 | Volume: 97 | Issue: 3 | Pages: 545-558

10.1227/neu.0000000000003391 | PMID 40079586 Get It

BACKGROUND AND OBJECTIVES: Schwannomas are benign, slow-growing peripheral nerve sheath tumors. Approximately 8% of intracranial schwannomas originate from the trigeminal nerve. No consensus exists regarding superiority of outcomes after resection vs stereotactic radiosurgery (SRS) in the treatment of trigeminal schwannomas (TS). The aim of this study was to compare the efficacy and outcomes of resection vs SRS for TS management. METHODS: Embase, PubMed, and SCOPUS databases were queried from the date of inception to July 2023 for primary data reporting TS treatment outcomes after SRS or resection. Risk of bias was reported under Newcastle-Ottawa Scale. RESULTS: Overall, 29 retrospective observational studies comprising 949 patients were included in the analysis. A total of 13 studies (n = 589) reported outcomes after SRS, and 16 studies (n = 360) reported outcomes after surgical resection, and 182 patients in the SRS group had previous resection. To ensure statistical validity of comparing the cohorts, 3 checkpoints were assessed: the median age (SRS: 48 vs surgery: 40 years old, P < .01), tumor volume (5.2 vs 8.9 cm 3 , P = .06), and median follow-up (53.9 vs 48.5 months, P = .59), which reflected the choice of treatment. Compared with surgical resection, the SRS group demonstrated significantly higher rates of facial hypesthesia improvement (44% vs 12%, P < .01) and lower rates of new onset (4% vs 15%, P = .051) at last follow-up. Facial pain was less likely to improve (58% vs 81%, P = .024) after SRS compared with surgery. However, worsened (5% vs 1%, P = .71) and new facial pain (2% vs 1%, P = .55) were comparable between cohorts. CONCLUSION: SRS seems to offer improvement in rates of hypesthesia and trigeminal motor deficits compared with surgical resection for TS. However, facial pain improvement was more favorable after surgery. These findings highlight the importance of individualized treatment decisions based on patient characteristics, tumor profile, and pretreatment symptoms.
Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: Third interim analysis of PSMAfore
Fizazi, Karim , Shore, N., Chi, K.N., Crosby, M. J., Roubaud, Guilhem, Fleming, Mark T. , Nordquist, L., Gauna, D.E. Castellano, Carnahan, Natalie, Ghebremariam, Samson, Hertelendi, Marianna , Eiber, Matthias , Morris, Michael J. , Bono, Johann S. de , Hermann, Ken , Nagarajah, James , Lewis, Brian E. , Sartor, Oliver

Mayo Clinic

Nuklearmedizin - NuclearMedicine | March 12, 2025 | Volume: 64 | Issue: 01 | Pages: 45-46

10.1055/s-0045-1804283 Get It

Acute sympathetic activation blunts the hyperemic and vasodilatory response to passive leg movement in young healthy males
Hanson, Brady E. , Lee, Joshua F., Garten, Ryan S. , Barrett‐O’Keefe, Zachary , Layec, Gwenaël , Ruple, Bradley A. , Richardson, Russell S. , Trinity, Joel D. , Trinity, Joel D , Wray, David Walter

Mayo Clinic

Physiological Reports | March 12, 2025 | Volume: 13 | Issue: 5 | Pages: No page available

10.14814/phy2.70180 | PMID 40017052 Get It

AbstractHeightened muscle sympathetic nerve activity (MSNA) contributes to impaired vasodilatory capacity and vascular dysfunction associated with aging and cardiovascular disease. The contribution of elevated MSNA to the vasodilatory response during passive leg movement (PLM) is not fully understood. This study tested the hypothesis that elevated MSNA diminishes the vasodilatory response to PLM in healthy young males (n = 11, 25 ± 2 yr). Post exercise circulatory occlusion (PECO) following 2 min of isometric handgrip (HG) exercise performed at 25% (ExPECO 25%) and 40% (ExPECO 40%) maximum voluntary contraction was used to incrementally engage the metaboreceptors and augment MSNA. Control trials were performed without PECO (ExCON 25% and ExCON 40%) to account for changes due to HG exercise. PLM was performed 2 min after exercise and hemodynamics were assessed. MSNA was recorded by microneurography in the peroneal nerve (n = 8). Measures of MSNA (i.e., burst incidences) increased during ExPECO 25% (+15 ± 5 burst/100 bpm) and ExPECO 40% (+22 ± 4 burst/100 bpm) and returned to pre‐HG levels during ExCON trials. Leg vascular conductance (vasodilation) during PLM was reduced by 16% and 44% during ExPECO 25% and ExPECO 40%, respectively. These findings indicate elevated MSNA attenuates the vasodilatory response to PLM and the magnitude of reduction in vasodilation during PLM is graded with the degree of sympathoexcitation.